Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19
- PMID: 33007478
- PMCID: PMC7524527
- DOI: 10.1016/j.cmi.2020.09.045
Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19
Abstract
Objectives: Use of corticosteroids is common in the treatment of coronavirus disease 2019, but clinical effectiveness is controversial. We aimed to investigate the association of corticosteroids therapy with clinical outcomes of hospitalized COVID-19 patients.
Methods: In this single-centre, retrospective cohort study, adult patients with confirmed coronavirus disease 2019 and dead or discharged between 29 December 2019 and 15 February 2020 were studied; 1:1 propensity score matchings were performed between patients with or without corticosteroid treatment. A multivariable COX proportional hazards model was used to estimate the association between corticosteroid treatment and in-hospital mortality by taking corticosteroids as a time-varying covariate.
Results: Among 646 patients, the in-hospital death rate was higher in 158 patients with corticosteroid administration (72/158, 45.6% vs. 56/488, 11.5%, p < 0.0001). After propensity score matching analysis, no significant differences were observed in in-hospital death between patients with and without corticosteroid treatment (47/124, 37.9% vs. 47/124, 37.9%, p 1.000). When patients received corticosteroids before they required nasal high-flow oxygen therapy or mechanical ventilation, the in-hospital death rate was lower than that in patients who were not administered corticosteroids (17/86, 19.8% vs. 26/86, 30.2%, log rank p 0.0102), whereas the time from admission to clinical improvement was longer (13 (IQR 10-17) days vs. 10 (IQR 8-13) days; p < 0.001). Using the Cox proportional hazards regression model accounting for time varying exposures in matched pairs, corticosteroid therapy was not associated with mortality difference (HR 0.98, 95% CI 0.93-1.03, p 0.4694).
Discussion: Corticosteroids use in COVID-19 patients may not be associated with in-hospital mortality.
Keywords: COVID-19; Corticosteroids; Outcome; SARS-CoV-2 pneumonia; Treatment.
Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Figures



Similar articles
-
Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.Clin Microbiol Infect. 2021 Jan;27(1):105-111. doi: 10.1016/j.cmi.2020.09.014. Epub 2020 Sep 22. Clin Microbiol Infect. 2021. PMID: 32971254 Free PMC article.
-
Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.JAMA Netw Open. 2021 Jul 1;4(7):e2114741. doi: 10.1001/jamanetworkopen.2021.14741. JAMA Netw Open. 2021. PMID: 34264329 Free PMC article.
-
Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients.Intern Emerg Med. 2021 Sep;16(6):1593-1603. doi: 10.1007/s11739-021-02655-6. Epub 2021 Feb 5. Intern Emerg Med. 2021. PMID: 33547620 Free PMC article.
-
Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes.Crit Care. 2020 Dec 14;24(1):696. doi: 10.1186/s13054-020-03400-9. Crit Care. 2020. PMID: 33317589 Free PMC article.
-
The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis.PLoS One. 2021 Apr 21;16(4):e0249481. doi: 10.1371/journal.pone.0249481. eCollection 2021. PLoS One. 2021. PMID: 33882090 Free PMC article.
Cited by
-
3D Bioprinting for Regenerating COVID-19-Mediated Irreversibly Damaged Lung Tissue.Int J Bioprint. 2022 Sep 13;8(4):616. doi: 10.18063/ijb.v8i4.616. eCollection 2022. Int J Bioprint. 2022. PMID: 36404781 Free PMC article. Review.
-
Continuous Renal Replacement Therapy With oXiris Filter May Not be an Effective Resolution to Alleviate Cytokine Release Syndrome in Non-AKI Patients With Severe and Critical COVID-19.Front Pharmacol. 2022 Feb 4;13:817793. doi: 10.3389/fphar.2022.817793. eCollection 2022. Front Pharmacol. 2022. PMID: 35185571 Free PMC article.
-
Comparative effect of different corticosteroids in severe community-acquired pneumonia: a network meta-analysis.BMC Pulm Med. 2025 Apr 30;25(1):210. doi: 10.1186/s12890-025-03679-w. BMC Pulm Med. 2025. PMID: 40307783 Free PMC article.
-
Developing and validating a machine learning prognostic model for alerting to imminent deterioration of hospitalized patients with COVID-19.Sci Rep. 2022 Nov 10;12(1):19220. doi: 10.1038/s41598-022-23553-7. Sci Rep. 2022. PMID: 36357439 Free PMC article.
-
Impact of Glucocorticoids on Cardiovascular System-The Yin Yang Effect.J Pers Med. 2022 Nov 3;12(11):1829. doi: 10.3390/jpm12111829. J Pers Med. 2022. PMID: 36579545 Free PMC article. Review.
References
-
- Phelan A.L., Katz R., Gostin L.O. The novel coronavirus originating in WUHAN, China: challenges for global health governance. JAMA. 2020;323:709–710. - PubMed
-
- Gorbalenya A.E., Baker S.C., Baric R.S., de Groot R.J., Drosten C., Gulyaeva A.A. Severe acute respiratory syndrome-related coronavirus: the species and its viruses – a statement of the coronavirus study group. bioRxiv. 2020 2020.2002.2007.937862.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous